[go: up one dir, main page]

AR101280A1 - Tieno[3,2-d]pirimidina, furo[3,2-d]pirimidina y pirrolo[3,2-d]pirimidinas útiles para el tratamiento de infecciones respiratorias por virus sincicial - Google Patents

Tieno[3,2-d]pirimidina, furo[3,2-d]pirimidina y pirrolo[3,2-d]pirimidinas útiles para el tratamiento de infecciones respiratorias por virus sincicial

Info

Publication number
AR101280A1
AR101280A1 ARP150102330A ARP150102330A AR101280A1 AR 101280 A1 AR101280 A1 AR 101280A1 AR P150102330 A ARP150102330 A AR P150102330A AR P150102330 A ARP150102330 A AR P150102330A AR 101280 A1 AR101280 A1 AR 101280A1
Authority
AR
Argentina
Prior art keywords
alkyl
substituted
independently
group
pyrimidine
Prior art date
Application number
ARP150102330A
Other languages
English (en)
Inventor
Siegel Dustin
L Mackman Richard
Oneil Hanrahan Clarke Michael
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AR101280A1 publication Critical patent/AR101280A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C07H11/04—Phosphates; Phosphites; Polyphosphates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06—Heterocyclic radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Se proveen aquí formulaciones, métodos y compuestos de tieno[3,2-d]pirimidina, furo[3,2-d]pirimidina, y pirrolo[3,2-d]pirimidina sustituidos de fórmula (1) para el tratamiento de infecciones por virus de Pneumovirinae, incluyendo infecciones por virus sincicial respiratorias, así como métodos e intermediarios para la síntesis del compuesto de tieno[3,2-d]pirimidina, furo[3,2-d]pirimidina, y pirrolo[3,2-d]pirimidina sustituidos. Reivindicación 1: Un compuesto de la fórmula (1), o una sal farmacéuticamente aceptable del mismo, caracterizado porque: X es seleccionado del grupo de O, S, NH, o N(C₁₋₆ alquilo); R¹ es seleccionado del grupo de H, CH₃, F, Cl, y NH₂; R² es seleccionado del grupo de F, Cl, ORᵃ, NHRᵃ, CN y N₃; R³ es seleccionado del grupo de CN, ORᵃ, C₁₋₆ alquilo, C₂₋₆ alquenilo, C₂₋₆ alquinilo, -CH₂-O-C₁₋₆ alquilo, -CH₂-S-C₁₋₆ alquilo, C₃₋₄ cicloalquilo, azido, halógeno, C₁₋₃ haloalquilo, SRᵃ, -CH₂-C₃₋₄ cicloalquilo, -O-C₃₋₄ cicloalquilo, y -O-C₁₋₃ haloalquilo; o cuando R² es ORᵃ, los dos grupos ORᵃ en las posiciones 2 y 3 juntos pueden formar con el anillo furanilo al cual están enlazados una estructura seleccionada del grupo de fórmulas (2); R⁴ es seleccionado del grupo de H, -C(=O)R⁶, -C(=O)OR⁶, y -C(=O)NR⁶R⁷; o R⁴ es un grupo de la fórmula (3); en donde: cada Y es O, S, NR, ⁺N(O)(R), N(OR), ⁺N(O)(OR), o N-NR²; y W¹ y W², cuando se toman juntos son -Y³(C(Rʸ)₂)₃Y³-; o uno de W¹ o W² junto con el grupo 3 hidroxi es -Y³- y el otro de W¹ o W² es la fórmula (4); o W¹ y W² son cada uno, independientemente, un grupo de la fórmula (4), en donde: cada Y¹ es, independientemente, O, S, NR, ⁺N(O)(R), N(OR), ⁺N(O)(OR), o N-NR²; cada Y² es independientemente un enlace, O, CR₂, -O-CR₂-, NR, ⁺N(O)(R), N(OR), ⁺N(O)(OR), N-NR², S, S-S, S(O), o S(O)₂; cada Y³ es independientemente O, S, o NR; M1 es 0, 1, 2, ó 3; cada Rˣ es independientemente Rʸ o la fórmula (5) en donde: cada M2a, M2b, y M2c es independientemente 0 ó 1; M2d es 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 ó 12; cada Rʸ es independientemente H, F, Cl, Br, I, OH, R, -C(=Y¹)R, -C(=Y¹)OR, -C(=Y¹)N(R)₂, -N(R)₂, -⁺N(R)₃, -SR, -S(O)R, -S(O)₂R, -S(O)(OR), -S(O)₂(OR), -OC(=Y¹)R, -OC(=Y¹)OR, -OC(=Y¹)(N(R)₂), -SC(=Y¹)R, -SC(=Y¹)OR, -SC(=Y¹)(N(R)₂), -N(R)C(=Y¹)R, -N(R)C(=Y¹)OR, -N(R)C(=Y¹)N(R)₂, -SO₂NR², -CN, -N₃, -NO₂, -OR, o W³; o cuando se toman juntos, dos Rʸs sobre el mismo átomo de carbono forman un anillo carbocíclico que tiene 3, 4, 5, 6, ó 7 átomos de carbono de anillo; o cuando se toman juntos, dos Rʸs sobre el mismo átomo de carbono forman junto con el átomo de carbono un heterociclo que tiene 3, 4, 5, 6, ó 7 átomos de anillo en donde un átomo de anillo es seleccionado de O ó N y todos los demás átomos de anillo son carbono; cada R es independientemente H, C₁₋₈ alquilo, C₁₋₈ alquilo sustituido, C₂₋₈ alquenilo, C₂₋₈ alquenilo sustituido, C₂₋₈ alquinilo, C₂₋₈ alquinilo sustituido, C₆₋₁₀ arilo, C₆₋₁₀ arilo sustituido, un heterociclo de 3 a 10 miembros, un heterociclo sustituido de 3 a 10 miembros, un heteroarilo de 5 a 12 miembros, un heteroarilo sustituido de 5 a 12 miembros, arilalquilo, arilaquilo sustituido, heteroarilalquilo, o heteroarilalquilo sustituido; y W³ es W⁴ o W⁵; W⁴ es R, -C(Y¹)Rʸ, -C(Y¹)W⁵, -SO₂Rʸ, o -SO₂W⁵; W⁵ es seleccionado de fenilo, naftilo, un carbociclo C₃₋₈, o un heterociclo de 3 a 10 miembros, en donde W⁵ es independientemente sustituido con grupos 0, 1, 2, 3, 4, 5, ó 6 Rʸ; cada R⁶ y R⁷ es independientemente H, C₁₋₈ alquilo, C₂₋₈ alquenilo, C₂₋₈ alquinilo, C₄₋₈ carbociclilalquilo, C₆₋₁₀ arilo, C₆₋₁₀ arilo sustituido, heteroarilo de 5 a 10 miembros, heteroarilo de 5 a 10 miembros sustituido, -C(=O)C₁₋₈ alquilo, -S(O)ₙ-C₁₋₈ alquilo o aril-C₁₋₈ alquilo; o R⁶ y R⁷ tomados juntos con un nitrógeno al cual están ambos unidos forman un heterociclo de 3 a 7 miembros en donde cualquier átomo de carbono de anillo de dicho heterociclo puede ser reemplazado opcionalmente con -O-, -S- o -NRᵃ-; y en donde cada C₁₋₈ alquilo, C₂₋₈ alquenilo, C₂₋₈ alquinilo o aril-C₁₋₈ alquilo de cada R⁶ o R⁷ es, independientemente, sustituido opcionalmente con uno, dos, tres o cuatro sustituyentes seleccionados de halo, hidroxi, CN, N₃, N(Rᵃ)₂ u ORᵃ; y en donde uno, dos o tres de los átomos de carbono no terminales de cada dicho C₁₋₈ alquilo puede ser reemplazado opcionalmente con -O-, -S- o -NRᵃ-; o R⁴ es un grupo seleccionado de los compuestos de fórmula (6) y (7), en donde: R⁸ es seleccionado de fenilo, 1-naftilo, 2-naftilo, el resto de fórmula (8) o el resto de fórmula (9); R⁹ es seleccionado de H y CH₃; R¹⁰ es seleccionado de H o C₁₋₆ alquilo; y R¹¹ es seleccionado de H, C₁₋₈ alquilo, bencilo, C₃₋₆ cicloalquilo, y CH₂-C₃₋₆ cicloalquilo; o R⁴ y el grupo 3 hidroxi se combina para formar la estructura seleccionada de las fórmulas (10) y (11).
ARP150102330A 2014-07-28 2015-07-22 Tieno[3,2-d]pirimidina, furo[3,2-d]pirimidina y pirrolo[3,2-d]pirimidinas útiles para el tratamiento de infecciones respiratorias por virus sincicial AR101280A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462029896P 2014-07-28 2014-07-28

Publications (1)

Publication Number Publication Date
AR101280A1 true AR101280A1 (es) 2016-12-07

Family

ID=53765598

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150102330A AR101280A1 (es) 2014-07-28 2015-07-22 Tieno[3,2-d]pirimidina, furo[3,2-d]pirimidina y pirrolo[3,2-d]pirimidinas útiles para el tratamiento de infecciones respiratorias por virus sincicial

Country Status (20)

Country Link
US (5) US9828388B2 (es)
EP (3) EP3693367B1 (es)
JP (3) JP2017523169A (es)
KR (1) KR102460181B1 (es)
CN (1) CN106573939B (es)
AR (1) AR101280A1 (es)
AU (1) AU2015298207C1 (es)
BR (1) BR112017001565A2 (es)
CA (1) CA2956571C (es)
EA (1) EA032490B1 (es)
ES (2) ES2910382T3 (es)
IL (1) IL249706A0 (es)
MX (1) MX2017001284A (es)
NZ (1) NZ727996A (es)
PL (2) PL3693367T3 (es)
PT (2) PT3174870T (es)
SG (1) SG11201700213SA (es)
SI (2) SI3174870T1 (es)
TW (1) TWI678369B (es)
WO (1) WO2016018697A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013001553B1 (pt) 2010-07-22 2021-01-12 Gilead Sciences, Inc. compostos antivirais para o tratamento de infecções por paramyxoviridae e composições farmacêuticas que os compreendem
TWI678369B (zh) * 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類
US20190022116A1 (en) 2014-12-26 2019-01-24 Emory University N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto
EP3324977B1 (en) 2015-07-22 2022-07-13 Enanta Pharmaceuticals, Inc. Benzodiazepine derivatives as rsv inhibitors
WO2017075590A2 (en) * 2015-10-30 2017-05-04 Cocrystal Pharma, Inc. Processes for preparing 2-dihalo ribolactones
CN110573518A (zh) * 2017-01-26 2019-12-13 尤拉·S·赞特里佐斯 被取代的双环嘧啶基化合物及其组合物和用途
EP3687543B1 (en) * 2017-09-29 2024-03-20 Enanta Pharmaceuticals, Inc. Combinations of pharmaceutical agents as rsv inhibitors
DK3706762T3 (da) 2017-12-07 2024-12-16 Univ Emory N4-hydroxycytidin og derivater og antivirale anvendelser relateret dertil
SG11202110137VA (en) 2019-03-18 2021-10-28 Enanta Pharm Inc Benzodiazepine derivatives as rsv inhibitors
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
CN118598916A (zh) 2020-02-18 2024-09-06 吉利德科学公司 抗病毒化合物
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
TWI883391B (zh) 2020-02-18 2025-05-11 美商基利科學股份有限公司 抗病毒化合物
CN111548384B (zh) * 2020-03-29 2021-04-27 常州安蒂卫生物科技有限公司 用于抗病毒治疗的被取代的n4-羟基胞苷衍生物及其前药
WO2022086840A1 (en) 2020-10-19 2022-04-28 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
CN117120444A (zh) 2021-04-16 2023-11-24 吉利德科学公司 使用酰胺制备卡巴核苷的方法
JP7719954B2 (ja) 2021-08-18 2025-08-06 ギリアード サイエンシーズ， インコーポレイテッド リン脂質化合物並びにその製造方法及び使用方法
TWI867455B (zh) 2022-03-02 2024-12-21 美商基利科學股份有限公司 用於治療病毒感染的化合物及方法
AR129003A1 (es) 2022-04-07 2024-07-03 Enanta Pharm Inc Compuestos heterocíclicos antivirales
WO2023211997A1 (en) 2022-04-27 2023-11-02 Enanta Pharmaceuticals, Inc. Antiviral compounds
US20250109157A1 (en) * 2023-09-28 2025-04-03 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5458A (en) 1848-02-22 Bench-vise
US135A (en) 1837-03-03 Jesse j
US3361306A (en) 1966-03-31 1968-01-02 Merck & Co Inc Aerosol unit dispensing uniform amounts of a medically active ingredient
US3565070A (en) 1969-02-28 1971-02-23 Riker Laboratories Inc Inhalation actuable aerosol dispenser
FR2224175B1 (es) 1973-04-04 1978-04-14 Isf Spa
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1017153B (it) 1974-07-15 1977-07-20 Isf Spa Apparecchio per inalazioni
SE438261B (sv) 1981-07-08 1985-04-15 Draco Ab Anvendning i dosinhalator av ett perforerat membran
US4584369A (en) * 1981-07-31 1986-04-22 Sloan-Kettering Institute For Cancer Research Anti-leukemic beta-glycosyl C-nucleosides
US4805811A (en) 1985-03-29 1989-02-21 Aktiebolaget Draco Dosage device
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US4955371A (en) 1989-05-08 1990-09-11 Transtech Scientific, Inc. Disposable inhalation activated, aerosol device for pulmonary medicine
ES2141108T3 (es) 1991-07-02 2000-03-16 Inhale Inc Metodo y dispositivo para proporcionar medicamentos en aerosol.
US5261538A (en) 1992-04-21 1993-11-16 Glaxo Inc. Aerosol testing method
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5388572A (en) 1993-10-26 1995-02-14 Tenax Corporation (A Connecticut Corp.) Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same
US5522385A (en) 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US5622163A (en) 1994-11-29 1997-04-22 Iep Group, Inc. Counter for fluid dispensers
US5544647A (en) 1994-11-29 1996-08-13 Iep Group, Inc. Metered dose inhalator
US6116234A (en) 1999-02-01 2000-09-12 Iep Pharmaceutical Devices Inc. Metered dose inhaler agitator
CN1968605A (zh) * 2004-06-15 2007-05-23 默克公司 作为rna依赖性rna病毒聚合酶抑制剂的c－嘌呤核苷类似物
WO2006050161A2 (en) 2004-10-29 2006-05-11 Biocryst Pharmaceuticals, Inc. Therapeutic furopyrimidines and thienopyrimidines
BRPI0717907A2 (pt) 2006-12-07 2013-11-05 Genentech Inc "composto, composição farmacêutica, métodos para tratar um câncer, para inbir ou modular a atividade da lipídeo quinase, processo para a produçãoo de uma composição farmacêutica, uso de um composto e kit"
PT2114980E (pt) 2007-01-12 2012-09-25 Biocryst Pharm Inc Análogos de nucleósidos anti-virais
ES2393038T3 (es) * 2007-05-10 2012-12-18 Biocryst Pharmaceuticals, Inc. Compuestos de tretrahidrofuro[3,4-D]dioxolano para su utlilización en el tratamiento de las infecciones víricas y del cáncer
CN100532388C (zh) * 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
WO2009132135A1 (en) 2008-04-23 2009-10-29 Gilead Sciences, Inc. 1' -substituted carba-nucleoside analogs for antiviral treatment
EP2313102A2 (en) 2008-07-03 2011-04-27 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
EA201200525A1 (ru) 2009-09-21 2012-09-28 Гайлид Сайэнсиз, Инк. 2'-фторзамещенные карба-нуклеозидные аналоги для противовирусного лечения
CN102596979B (zh) 2009-09-21 2014-12-10 吉里德科学公司 用于制备1’-取代碳核苷类似物的方法和中间体
US8455451B2 (en) 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
WO2012012465A1 (en) 2010-07-19 2012-01-26 Clarke, Michael, O'neil Hanrahan Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
BR112013001553B1 (pt) * 2010-07-22 2021-01-12 Gilead Sciences, Inc. compostos antivirais para o tratamento de infecções por paramyxoviridae e composições farmacêuticas que os compreendem
CN102351931B (zh) * 2010-09-07 2014-01-22 河南省科学院高新技术研究中心 嘧啶核苷衍生物、合成方法及其在制备抗肿瘤、抗病毒药物中的应用
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
TW201305185A (zh) 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之２’－氟取代之碳－核苷類似物
JP2013538230A (ja) * 2010-09-20 2013-10-10 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス治療用の２’−フルオロ置換カルバヌクレオシド類似体
CA2812962C (en) * 2010-09-22 2020-03-31 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
MX348759B (es) 2010-10-15 2017-06-28 Biocryst Pharm Inc Metodos y composiciones para inhibicion de polimerasa.
TW201306841A (zh) 2010-12-20 2013-02-16 Gilead Sciences Inc 治療ｃ型肝炎病毒（ｈｃｖ）之方法
EP2697242B1 (en) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
CN103748098B (zh) * 2011-10-11 2016-06-29 弗·哈夫曼-拉罗切有限公司 用于治疗或预防呼吸道合胞病毒疾病的化合物
GEP20166496B (en) 2011-12-22 2016-06-27 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
PL2834258T3 (pl) 2012-03-13 2017-07-31 Gilead Sciences, Inc. 2'- podstawione analogi karba-nukleozydów do leczenia przeciwwirusowego
NZ629428A (en) * 2012-03-21 2016-10-28 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
UA119050C2 (uk) * 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
TWI678369B (zh) * 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類

Also Published As

Publication number Publication date
EA032490B1 (ru) 2019-06-28
PT3174870T (pt) 2020-07-03
EP4023650A1 (en) 2022-07-06
ES2802175T3 (es) 2021-01-15
US20250042913A1 (en) 2025-02-06
US20250270229A1 (en) 2025-08-28
SG11201700213SA (en) 2017-02-27
PL3693367T3 (pl) 2022-05-16
SI3693367T1 (sl) 2022-05-31
ES2910382T3 (es) 2022-05-12
CN106573939A (zh) 2017-04-19
AU2015298207A1 (en) 2017-02-02
JP2017523169A (ja) 2017-08-17
EP3174870A1 (en) 2017-06-07
EA201790146A1 (ru) 2017-06-30
US10501476B2 (en) 2019-12-10
EP3174870B1 (en) 2020-04-15
JP6991188B2 (ja) 2022-01-12
JP2020023590A (ja) 2020-02-13
CA2956571C (en) 2023-09-05
TW201617350A (zh) 2016-05-16
PL3174870T3 (pl) 2020-10-19
EP3693367B1 (en) 2022-02-16
NZ727996A (en) 2018-06-29
MX2017001284A (es) 2017-05-23
US10179794B2 (en) 2019-01-15
US20160024107A1 (en) 2016-01-28
US20190194223A1 (en) 2019-06-27
KR102460181B1 (ko) 2022-10-31
BR112017001565A2 (pt) 2018-01-30
JP2022010149A (ja) 2022-01-14
US20180072755A1 (en) 2018-03-15
WO2016018697A1 (en) 2016-02-04
US9828388B2 (en) 2017-11-28
AU2015298207B2 (en) 2018-02-15
PT3693367T (pt) 2022-06-27
TWI678369B (zh) 2019-12-01
EP3693367A1 (en) 2020-08-12
KR20170031246A (ko) 2017-03-20
AU2015298207C1 (en) 2018-09-20
CA2956571A1 (en) 2016-02-04
IL249706A0 (en) 2017-02-28
CN106573939B (zh) 2019-10-22
SI3174870T1 (sl) 2020-08-31

Similar Documents

Publication Publication Date Title
AR101280A1 (es) Tieno[3,2-d]pirimidina, furo[3,2-d]pirimidina y pirrolo[3,2-d]pirimidinas útiles para el tratamiento de infecciones respiratorias por virus sincicial
AR101561A1 (es) Nucleósidos de 2-cloro aminopirimidinona y pirimidina diona
AR129635A2 (es) Moduladores de tetrahidropiridopirazina de gpr6
AR104176A1 (es) Inhibidores de ido (indolamina-2,3-dioxigenasa)
AR093505A1 (es) Derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina que contienen un grupo sulfoximina
AR103222A1 (es) Procedimiento para la preparación de análogos de 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidina
AR100160A1 (es) 1H-PIRROLO[2,3-c]PIRIDIN-7(6H)-ONAS Y PIRAZOLO[3,4-c]PIRIDIN-7(6H)-ONAS COMO INHIBIDORES DE PROTEÍNAS BET
AR096979A1 (es) Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR105648A1 (es) Métodos para la preparación de ácidos biliares y derivados de los mismos
AR094174A1 (es) Lactamas fusionadas de arilo y heteroarilo
AR097431A1 (es) Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de quinasas pim
PE20171341A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas
AR092349A1 (es) Imidazotriazincarbonitrilos utiles como inhibidores de quinasa
AR107032A1 (es) Inhibidores bicíclicos de pad4
AR106798A1 (es) Inhibidores pirazol de acc y usos de los mismos
AR088423A1 (es) Ligadores p1 ciclicos como inhibidores del factor xia
AR106806A1 (es) Inhibidores triazol de acc y usos de los mismos
AR120246A1 (es) Aminas heteroaril-bifenilas para el tratamiento de las enfermedades por pd-l1
EA201592126A1 (ru) 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
AR089285A1 (es) Derivados de betulina
AR084976A1 (es) Compuestos de bifenileno sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
AR090955A1 (es) Aminas biciclicas c-17 de triterpenoides con actividad inhibidora de la maduracion del vih
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR088320A1 (es) Derivados de isoindolinona y pirrolopiridinona como inhibidores de akt
AR097199A1 (es) Inhibidores de rorc2 y sus métodos de uso

Legal Events

Date Code Title Description
FB Suspension of granting procedure